country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-150596

Copy Link Print Information

CT1-3

CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating JNK/Bcl-2/Bax/XIAP pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 2460738-32-1
Formel: C₂₅H₂₉NO₃S₂
Molecular Weight:455.63

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (270 KB)

CT1-3 Chemical Structure

CAS. Nr.: 2460738-32-1

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen :

Alle JNK Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	9.07 μM Compound: CT1-3	Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
AGS	IC₅₀	8.02 μM Compound: CT1-3	Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
HepG2	IC₅₀	6.24 μM Compound: CT1-3	Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
HONE1 cell line	IC₅₀	14.06 μM Compound: CT1-3	Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
LoVo	IC₅₀	5.1 μM Compound: CT1-3	Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MCF7	IC₅₀	12.72 μM Compound: CT1-3	Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
MDA-MB-231	IC₅₀	7.48 μM Compound: CT1-3	Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1299	IC₅₀	9.17 μM Compound: CT1-3	Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H1650	IC₅₀	6.92 μM Compound: CT1-3	Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
NCI-H460	IC₅₀	6.15 μM Compound: CT1-3	Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
OVCAR-3	IC₅₀	5.34 μM Compound: CT1-3	Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
SGC-7901	IC₅₀	11.47 μM Compound: CT1-3	Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
SW480	IC₅₀	6.07 μM Compound: CT1-3	Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]
U-251	IC₅₀	7.75 μM Compound: CT1-3	Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay	[PMID: 32416457]

In Vitro

CT1-3 has excellent inhibitory activity against multiple cancer cells with IC₅₀ range of 5.10~14.06 μM in LOVO, A549, HepG2, MDA-MB-231 and HONE1, et al^[1].
CT1-3 (10 μM; 24 h) notably increases ROS production in HCCs, significantly decreases mitochondrial membrane potential, and reduces Bcl-2 and XIAP levels and increases phospho-JNK and Bax levels^[1].
CT1-3 (7.5 μM; 24 h) reduces the capacity of migration and invasion of HCCs, significantly promotes the expression level of E-cadherin (E-cad), and markedly decreases the pro-metastatic and pro-invasive protein Snail^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

A549, H460 and LOVO
Concentration:

10 μM
Incubation Time:

24 h
Result:

Notably increased ROS production, significantly decreased mitochondrial membrane potential, and reduced Bcl-2 and XIAP levels and increased phospho-JNK and Bax levels.

In Vivo

CT1-3 (20 mg/kg; IP, for 28 days) significantly suppresses tumor growth and exhibits no hepatic and renal toxicity in MDA-MB-231 xenografts model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male BALB/c-nu/nu mice (injected with A549, OVCAR3 and MDA-MB-231)^[1]
Dosage:

20 mg/kg
Administration:

IP, for 28 days
Result:

Significantly suppresses tumor growth and exhibited no hepatic and renal toxicity.

Chemical Information

CAS. Nr. 2460738-32-1
Molecular Weight 455.63
Formel C₂₅H₂₉NO₃S₂
SMILES

OC1=CC=C(CC=C)C=C1C2=CC(CC=C)=CC=C2OCCS(CCCCN=C=S)=O
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (270 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Tao C, et al. CT1-3, a novel magnolol-sulforaphane hybrid suppresses tumorigenesis through inducing mitochondria-mediated apoptosis and inhibiting epithelial mesenchymal transition. Eur J Med Chem. 2020 Aug 1;199:112441. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

CT1-3

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen

Alle JNK Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

CT1-3 Related Classifications

HY-150596 Related Classifications